Knowledge of ayahuasca pharmacology and effects

The manuals converge on the core pharmacology of ayahuasca, especially that it contains DMT and beta-carbolines such as harmine, and that these components are central to its effects. Across the extracts, DMT is linked with serotonergic activity, specifically 5-HT2A agonism or central serotonergic agonist activity, while harmine is described as a monoamine oxidase A inhibitor. The sources also agree that ayahuasca is hallucinogenic and can produce increased psychoactivity, with one extract explicitly linking the combined MAO inhibition and serotonergic effects to psychoactive and antidepressant actions. The manuals differ mainly in emphasis and level of detail. One source gives a concise receptor level summary, naming DMT and harmine and their basic actions, while another expands the botanical composition by identifying Banisteriopsis caapi as containing harmine, tetrahydroharmine, and harmaline, and Psychotria viridis as containing DMT. The ICEERS guide is broader and more practice oriented, focusing on knowing the ingredients, understanding the strength or potency of the brew before administering it, and being able to explain the properties, composition, and effects to participants. There is also a difference in clinical framing. The depression studies connect the pharmacology to clinical response, including antidepressant effects and the need to anticipate risks and clinical responses, whereas the good practice guide stays at the level of preparation, dosing, and risk explanation.